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Background: Nonsteroidal anti-inﬂammatory drugs are the ﬁrst-line option for treating ankylosing
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Objective: To evaluate the efﬁcacy and safety of 6 weeks’ treatment with celecoxib in patients with AS
in China.
Methods: This Phase 3, double-blind, parallel-group study randomized patients with AS aged Z18 to 65
years 1:1 to receive celecoxib 200 mg once daily or diclofenac sustained release 75 mg once daily. After
6 weeks, patients could use celecoxib 400 mg once daily or maintain blinded therapy. The primary
efﬁcacy end point was mean change from baseline at Week 6 for Patient’s Global Assessment of Pain
Intensity score (100-mm visual analog scale). Noninferiority was established if the upper bound of the CI
was o10 mm. Secondary objectives included patients’ and physicians’ assessments of disease activity,
change from baseline in C-reactive protein level, and safety.
Results: In the per-protocol analysis set the least squares mean change from baseline in the Patient’s
Global Assessment of Pain Intensity score at Week 6 was –23.8 mm and –27.1 mm in patients receiving
celecoxib (n ¼ 111) and diclofenac (n ¼ 108), respectively. The 2-sided 95% CI for the treatment
difference (celecoxib – diclofenac) was –2.2 to 8.8. Overall, 4.2% and 6.7% of patients in the celecoxib and
diclofenac groups, respectively, reported treatment-related adverse events. All were mild to moderate in
severity.
Conclusions: Celecoxib 200 mg once daily is noninferior to diclofenac sustained release 75 mg once daily
for pain treatment in Chinese patients with AS. ClinicalTrials.gov identiﬁer: NCT00762463.
& 2014. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Ankylosing spondylitis (AS) is a chronic inﬂammatory disease
of the axial skeleton manifested by inﬂammatory back pain,
progressive stiffness of the spine, arthritis, enthesitis, and acute
anterior uveitis.1,2 Symptoms of AS traditionally appear during lateInc. This is an open access article u
epartment of Rheumatology,
100853, China.
g).adolescence and early adulthood, and the condition is a signi-
ﬁcant health burden in young male adults.3 If the disease is
undiagnosed or inadequately treated, patients with AS may
experience continuous pain, stiffness, fatigue, and a progressive
loss of spinal mobility and function, which ultimately leads to a
reduction in quality of life.4 The 1984 modiﬁed New York criteria
describe the classiﬁcation criteria for AS.5 Patients may be diag-
nosed with AS if characteristic radiologic changes of the sacroiliac
joint are present, together with deﬁned clinical symptoms and
physical ﬁndings.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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the mainstay of treatment for AS.6 In China, where the prevalence
of AS is 0.3%,7 nonselective (ns) NSAIDs and tumor necrosis factor-
α (TNFα) antagonists are approved AS treatments. In addition, a
number of other medications, including disease-modifying anti-
rheumatic drugs, opioids, and muscle relaxants are prescribed for
the treatment of patients with AS.7 However, evidence suggests
that, particularly over the longer term, the use of nsNSAIDs and
injectable TNFα antagonists may be limited by the concern for
adverse events (AEs) and other undesirable effects.8,9 The use of
nsNSAIDs has been associated with AEs affecting the gastrointes-
tinal (GI) tract8 and cardiovascular system,10–13 with diclofenac
being associated with a particularly high risk of cardiovascular
adverse events.11 In addition, nsNSAIDs are also believed to
exacerbate inﬂammatory bowel disease that often accompanies
spondyloarthropathies.14–18 Although injectable TNFα antagonists
have been shown to be effective treatments for the signs and
symptoms of AS,19,20 the cost of use, inconvenience of adminis-
tration, and possible safety concerns9 may limit their use to
refractory or severe cases.
Compared with nsNSAIDs, which inhibit both cyclooxygenase
(COX)-1 and COX-2, the COX-2 selective NSAIDs are thought to
have a superior GI safety proﬁle21 because they selectively inhibit
COX-2–mediated production of inﬂammatory mediators while
preserving the integrity of the gastroduodenal mucosa (through
COX-1 mediated synthesis of prostanoids).22 Furthermore, the rate
of cardiovascular AEs has been demonstrated to be comparable to
that of nsNSAIDs in a meta-analysis.23
Outside of China, the COX-2 selective NSAID celecoxib has been
evaluated in 2 double-blind, randomized, controlled, active-
comparator trials in patients with AS.24,25 However, to date, no
large-scale randomized controlled trials have been conducted in
China, where there is a paucity of efﬁcacy and safety data for this
treatment. Therefore the primary objective of our study was to
demonstrate noninferiority of celecoxib 200 mg once daily com-
pared with diclofenac sustained release (SR) 75 mg once daily in
the treatment of Chinese patients with AS in terms of pain
assessment after 6 weeks of treatment.Patients and Methods
Study design
Our study (ClinicalTrials.gov identiﬁer NCT00762463) was a
randomized, active-comparator, double-blind, parallel-group, non-
inferiority study conducted at 5 centers across China. The protocol
was approved by the institutional review board or independentCelecoxib 200 mg once dai
Diclofenac SR 75 mg once 
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Figure 1. Study design. NSAID ¼ nonsteroidal antethics committee at each center, and the study was conducted in
accordance with the principles of the Declaration of Helsinki, the
International Conference on Harmonisation guidelines for Good
Clinical Practice, and local regulatory requirements. The study
consisted of a double-blind treatment period lasting 6 weeks,
followed by a 6-week extension period. All patients provided
written informed consent before any screening procedures were
performed.
The study included a total of 6 study visits: screening visit (Visit
1), baseline visit (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week
6 (Visit 5), and Week 12 (Visit 6 for those enrolled in the extension
period) or when the study drug was terminated (end-of-treatment
visit) (Figure 1). However, unscheduled visits were possible at any
time during the study treatment if required.
The primary objective was to demonstrate noninferiority of
celecoxib 200 mg once daily compared with diclofenac SR 75 mg
once daily in the treatment of patients with AS in the per-protocol
analysis set population, in terms of their pain assessment at Week 6.
Diclofenac was chosen as the active comparator in this study because
it is commonly used to treat AS.26 A dose of 75 mg diclofenac SR once
daily was chosen to minimize the emergence of AEs that have been
associated with the higher dose of 150 mg daily.27,28
Patients
Adult male and female patients aged 18 to 65 years were
eligible for inclusion if they had AS according to the 1984 modiﬁed
New York criteria for classiﬁcation of AS.5 In addition, all patients
must have had a diagnosis of AS with axial involvement but
without peripheral joint involvement (synovitis) at the time of
study entry. Patients were required to have been receiving daily
treatment with NSAIDs 30 days before study entry. Patients were
excluded if they had known inﬂammatory enteropathy, the pres-
ence of other extra-articular manifestations, known vertebral
compression, or the need to wear a corset during the study. In
addition, patients were excluded if they required the use of
concomitant muscle relaxants, hypnotics, anxiolytics, sedatives,
tranquillizers, or antidepressant drugs, or the concomitant use of
anticoagulants, ticlopidine, lithium, aspirin 4150 mg/d, metho-
trexate 415 mg/wk, prednisolone 410 mg/d (or equivalent dose
of other corticosteroids), NSAIDs, or COX-2 inhibitors (other than
study drug or biologics). Women with childbearing potential were
required to have been using adequate contraception.
Treatment
Patients were randomized 1:1 to receive either celecoxib 200
mg once daily or diclofenac SR 75 mg once daily for 6 weeksly
daily
inophen/paracetamol) allowed
Celecoxib 400 mg once daily
or
maintenance of
double-blind therapy 
4
d period
 4 Week 6 Week 12
Extension phase
Visit 5 Visit 6
i-inﬂammatory drug; SR ¼ sustained release.
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generated schedule that generated a random permuted-blocks
design. Each patient qualifying for a treatment assignment was
given the next consecutive number within a center and was
dispensed the corresponding study medication. To ensure that
the treatment remained blinded to the investigators and patients
during the double-blind period, a double-dummy method of
blinding was used (celecoxib 200 mg capsules, diclofenac SR 75
mg tablets, and their respective matching placebos were similar in
size, color, smell, taste, and appearance). Rescue medication in the
form of acetaminophen/paracetamol could be taken on demand,
but the dose could not exceed a total daily dose of 2 g.
All patients who exhibited no study medication-related AEs
were offered extension treatment at the end of the 6-week,
double-blind period; patients in the celecoxib 200 mg once daily
(C200) and diclofenac SR 75 mg once daily (D75) groups received
either open-label celecoxib 400 mg once daily (herein referred to
as the C200/C400 or D75/C400 group) or continuation of their
double-blind period therapies (herein referred to as the C200 or
D75 no treatment change [NTC] groups) for an additional 6 weeks.
In the extension phase, assignment to celecoxib 400 mg once daily
was open to the investigators, patients, and the sponsor’s study
team. Patients who maintained their celecoxib 200 mg once daily
or diclofenac SR 75 mg once daily therapies were dispensed
medication in the same manner they had received medication
during the double-blind phase. These patients remained blinded to
the study medication assignments. Dose adjustments were not
permitted during the study and extension period.
Efﬁcacy evaluations
The primary end point was the mean change from baseline at
Week 6 during the double-blind treatment period in the Patient’s
Global Assessment of Pain Intensity score. The Patient’s Global
Assessment of Pain Intensity score was based on a 100-mm visual
analog scale (VAS) pain scale where 0 ¼ no pain and 100 ¼ worst
possible pain. The secondary end points were the change from
baseline at Weeks 2, 4, and 6 in the Patient’s Global Assessment of
Pain Intensity score, the Patient’s Global Assessment of Disease
Activity score (measured on a 5-point Likert scale where 1 ¼ very
good and 5 ¼ very poor), the Physician’s Global Assessment of
Disease Activity score (measured on a 5-point Likert scale where
1 ¼ very good and 5 ¼ very poor), the Bath Ankylosing
Spondylitis Functional Index score (comprising a series of 10
speciﬁc questions, each answered on a 100-mm VAS where 0 ¼
easy and 100 ¼ impossible), the Bath Ankylosing Spondylitis
Disease Activity Index score (comprising a series of 6 questions),
nocturnal pain, the distance from ﬁngertips to ﬂoor (measured in
centimeters), chest expansion (measured in centimeters), Assess-
ment in Ankylosing Spondylitis (ASAS-20) score, and measures of
the change from baseline at Week 6 in erythrocyte sedimentation
rate (ESR) and C-reactive protein (CRP) level.
Safety evaluations
Safety evaluations included monitoring of AEs, treatment dis-
continuations, and the use of concomitant medications, measure-
ment of vital signs, a physical examination, and the assessment of
clinical laboratory investigations. The speciﬁc laboratory assess-
ments included hematology measurements, urine tests, and clin-
ical chemistry measurements.
Statistical analysis
SAS (version 9.0, SAS Institute Inc, Cary, North Carolina) was
used for all analyses. The sample size calculation for this study wasbased on the primary end point, the Patient’s Global Assessment of
Pain Intensity score at Week 6, and the hypothesis that celecoxib
200 mg once daily was noninferior to diclofenac SR 75 mg once
daily. Based on the following assumptions, the noninferiority
margin was 10 mm, the SD of pain intensity change from baseline
at Week 6 was no more than 25 mm (based on Week 6 data from
previously published25 and, as yet unpublished [COXA-0506-247],
studies), and the power and signiﬁcance level for the noninferiority
test were 80% and 0.025 (1-sided), respectively, a sample size of 100
patients per-protocol analysis set in each treatment group was
required. The noninferiority margin was selected a priori.
The primary efﬁcacy analysis was performed on the per-protocol
analysis set, which comprised all randomized and treated patients
who had a global pain intensity assessment at Week 6 and had no
major protocol deviations during the 6-week, double-blind period.
The primary end point was analyzed using analysis of covariance
with treatment group and study center as factors and the baseline
Patient’s Global Assessment of Pain Intensity score as a covariate. A
2-sided 95% CI was constructed for the least squares (LS) mean
difference on the primary end point between celecoxib 200 mg
once daily and diclofenac SR 75 mg once daily. Noninferiority was
declared if the upper bound of the 95% CI was o10 mm.
All secondary efﬁcacy end point analyses were performed on
the full analysis set, which comprised all randomized patients who
received at least 1 dose of study treatment.
Safety analyses were performed on all randomized patients
who received at least 1 dose of study medication. For the extension
period the efﬁcacy and safety analyses were analyzed separately.Results
Patients
Overall, 255 patients were screened, of which 240 patients
were randomized and received treatment (Figure 2). In total, 240
patients were included in the full analysis set, and 219 were
included in the per-protocol analysis set for the efﬁcacy analyses
during the 6-week double-blind treatment phase.
A total of 218 patients entered the extension period, of which
6 withdrew from the celecoxib 400 mg once daily group (4 in the
C200/C400 group and 2 in the D75/C400 group). Of patients in the
NTC population, 3 withdrew from the C200 NTC group, and
1 withdrew from the D75 NTC group.
At baseline, 85.8% of patients (206 out of 240) were male. Other
baseline characteristics were similar between the 2 treatment
groups (Table I). In terms of prior NSAID use, 36.7% of patients
(44 out of 120) in the celecoxib 200 mg once daily and 35.0% (42
out of 120) in the diclofenac SR 75 mg once daily groups were
receiving either diclofenac or diclofenac sodium before the start of
the study.
Efﬁcacy
Patient’s Global Assessment of Pain Intensity
For the primary end point in the per protocol analysis set, the
LS mean change from baseline in the Patient’s Global Assessment
of Pain Intensity score (using a VAS) at Week 6 (per-protocol
analysis set; Week 6 – baseline) was –23.8 mm and –27.1 mm in
the celecoxib 200 mg once daily and diclofenac SR 75 mg once
daily groups, respectively (Figure 3). The treatment difference
(celecoxib – diclofenac SR) at Week 6 in the per-protocol analysis
set was 3.3 mm and the 2-sided 95% CI for the treatment differ-
ence was (–2.2 to 8.8 mm). Because the upper bound of the 95% CI
was o10 mm, celecoxib was noninferior to diclofenac in the
treatment of Chinese patients with AS.
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Figure 2. Flow of patients through the study. SR ¼ sustained release.
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from baseline was –28.4 mm in the C200 group and –30.9 mm in
the D75 group. The treatment effect achieved by both treatment
groups at the end of the 6-week double-blind period was main-
tained through Week 12.
The Patient’s Global Assessment of Pain Intensity scores at Weeks
2, 4, and 6 for the full analysis set are summarized in Table II.Table I
Baseline patient demographics and disease characteristics (full analysis set).
Patient demographic Celecoxib 200 mg once daily (n ¼ 120)
Men (n ¼ 105) Women (n ¼ 15)
Age, y
18–44* 97 (92.4) 12 (80.0)
45–64* 8 (7.6) 3 (20.0)
Mean (SD) 29.5 (8.9) 31.6 (10.7)
Range 18–58 19–53
Weight, kg
Mean (SD) 66.5 (11.8) 52.1 (7.3)
Range 47.0–108.0 35.0–62.0
Body mass index
Mean (SD) 22.7 (3.6) 20.1 (2.3)
Range 17.2–34.5 15.6–23.4
Height, cm
Mean (SD) 170.9 (5.4) 160.9 (5.5)
Range 158.0–185.0 150.0–175.0
SR ¼ sustained release.
n Values are given as n (%) unless otherwise noted.Patient’s Global Assessment of Disease Activity
The Patient’s Global Assessment of Disease Activity scores at
Weeks 2, 4, and 6 are summarized in Table III. At the end of the
extension phase (Week 12), the mean (SD) change from baseline
was –0.6 (1.0) in the celecoxib group and –0.6 (0.8) in the
diclofenac SR group. In patients who changed treatment during
the extension period, the mean change from baseline at Week 6 inDiclofenac SR 75 mg once daily (n ¼ 120) Total (N ¼ 240)
Men (n ¼ 101) Women (n ¼ 19)
91 (90.1) 18 (94.7) 218 (90.8)
10 (9.9) 1 (5.3) 22 (9.2)
28.8 (9.1) 29.5 (7.2) 29.3 (9.0)
18–59 20–45 18–59
66.3 (11.8) 53.4 (9.7) 64.5 (12.3)
46.0–93.0 42.0–75.0 35.0–108.0
22.4 (3.5) 21.0 (3.5) 22.3 (3.6)
16.0–31.5 16.2–27.9 15.6–34.5
171.9 (5.9) 159.4 (4.5) 169.8 (6.8)
150.0–184.0 150.0–170.0 150.0–185.0
Change from baseline at Week 6
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Figure 3. Changes from baseline in Patient’s Global Assessment of Pain Intensity
score (per-protocol analysis set) at Week 6. LS ¼ least squares; SR ¼ sustained
release.
Table III
Patient’s Global Assessment of Disease Activity score at baseline to Week 2, 4, and
6 in the double-blind period (full analysis set).
Characteristic Celecoxib 200
mg once daily
(n ¼ 120)
Diclofenac SR
75 mg once
daily (n ¼ 120)
Difference (celecoxib 200
mg once daily – diclofenac
SR 75 mg once daily)
Baseline
N 117 115
Mean (SD) 3.2 (0.73) 3.1 (0.67)
Change from
baseline to
Week 2
N 116 115
Mean (SD) –0.4 (0.72) –0.4 (0.72)
LS mean (SE)* –0.4 (0.06) –0.4 (0.06) 0.0 (0.08)
95% CI† –0.5 to –0.3 –0.5 to –0.3 –0.15 to 0.17
P value* – – 0.8938
Change from
baseline to
Week 4
N 117 115
Mean (SD) –0.3 (0.74) –0.4 (0.67)
LS mean (SE) –0.3 (0.06) –0.4 (0.06) 0.2 (0.08)
95% CI –0.4 to –0.2 –0.5 to –0.3 0.01 to 0.31
P value – – 0.0426
Change from
baseline to
Week 6
N 117 115
Mean (SD) –0.3 (0.76) –0.4 (0.74)
LS Mean (SE) –0.3 (0.06) –0.4 (0.06) 0.1 (0.09)
95% CI –0.4 to –0.2 –0.5 to –0.3 –0.05 to 0.29
P value – – 0.1502
LS ¼ least squares; SR ¼ sustained release.
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group. At Week 12 there was an improvement from Week 6 in the
mean change from baseline in the C200/C400 group (–0.1 [0.7] at
Week 6 vs –0.4 [0.7] at Week 12) and in the D75/C400 group (–0.4
[0.7] at Week 6 vs –0.6 [1.0] at Week 12).Table II
Patient’s Global Assessment of Pain Intensity score at baseline to Week 2, 4, and
6 in the double-blind period (full analysis set).
Characteristic Celecoxib 200
mg once daily
(n ¼ 120)
Diclofenac SR
75 mg once
daily (n ¼ 120)
Difference (celecoxib 200
mg once daily – diclofenac
SR 75 mg once daily)
Baseline
N 117 115
Mean (SD) 63.1 (12.84) 63.7 (13.28)
Change from
baseline to
Week 2
N 116 115
Mean (SD) –18.4 (19.39) –17.7 (19.69)
LS mean (SE)* –18.6 (1.78) –17.9 (1.79) –0.7 (2.5)
95% CI† –22.1 to –15.0 –21.4 to –14.3 –5.6 to 4.2
P value* – – 0.7849
Change from
baseline to
Week 4
N 117 115
Mean (SD) –20.7 (20.52) –23.4 (21.61)
LS mean (SE) –20.7 (1.86) –23.3 (1.89) 2.6 (2.62)
95% CI –24.4 to –17.0 –27.1 to –19.6 –2.6 to 7.8
P value – – 0.3223
Change from
baseline to
Week 6
N 117 115
Mean (SD) –23.7 (20.61) –26.7 (22.85)
LS mean (SE) –23.8 (1.92) –26.8 (1.95) 3.1 (2.71)
95% CI –27.5 to –20.0 –30.7 to –23.0 –2.3 to 8.4
P value – – 0.2598
LS ¼ least squares; SR ¼ sustained release.
n Estimated from analysis of covariance model with treatment and center as
factors and baseline as covariate.
† Noninferiority considered if the upper bound of the CI o10.
n Estimated from analysis of covariance model with treatment and center as
factors and baseline as covariate.
† Noninferiority considered if the upper bound of the CI o10.Physician’s Global Assessment of Disease Activity
The Physician’s Global Assessment of Disease Activity scores at
Weeks 2, 4 and 6 are summarized in Table IV. At the end of the
extension phase (Week 12), the mean (SD) change from baseline
was –0.7 (0.6) in the C200 group and –0.5 (0.6) in the D75 group.
At Week 12 there was an improvement from Week 6 in the mean
change from baseline in the C200/C400 group (–0.2 [0.6] at Week
6 vs –0.5 [0.5] at Week 12) and in the D75/C400 group (–0.5 [0.7]
at Week 6 vs –0.7 [0.8] at Week 12).Bath Ankylosing Spondylitis Functional Index
The LS mean (SE) change from baseline at Week 6 in Bath
Ankylosing Spondylitis Functional Index score was –0.5 (0.2) and
–0.8 (0.2) in the celecoxib and diclofenac SR groups, respectively
(treatment difference and 2-sided 95% CI; 0.3 [–0.1 to 0.7]). At
Week 12, the mean change from baseline was –0.9 (1.8) in the C200
group and –1.0 (1.6) in the D75 group. In patients who changed
treatment during the extension period, the mean change from
baseline at Week 6 in the C200/C400 group was noticeably smaller
than in the C200 group. At Week 12, there was an improvement
from Week 6 in the mean change from baseline in the C200/C400
group (–0.2 [1.8] at Week 6 vs –0.6 [2.0] at Week 12) and in the
D75/C400 group (–0.8 [2.1] at Week 6 vs –1.0 [2.3] at Week 12).Bath Ankylosing Spondylitis Disease Activity Index
The LS mean (SE) change from baseline at Week 6 in Bath
Ankylosing Spondylitis Disease Activity Index was –1.1 (0.2) in the
celecoxib group and –1.4 (0.2) in the diclofenac SR group (treat-
ment difference ¼ 0.3; 2-sided 95% CI, –0.1 to 0.8). At Week 12, the
mean change from baseline was –1.7 (1.9) in the C200 group and
–2.1 (1.9) in the D75 group. In patients who changed treatment
Table IV
Physician’s Global Assessment of Disease Activity score at baseline to Week 2, 4,
and 6 in the double-blind period (full analysis set).
Characteristic Celecoxib 200
mg once daily
(n ¼ 120)
Diclofenac SR
75 mg once
daily (n ¼ 120)
Difference (celecoxib 200
mg once daily – diclofenac
SR 75 mg once daily)
Baseline
N 117 115
Mean (SD) 3.2 (0.51) 3.2 (0.52)
Change from
baseline to
Week 2
N 116 115
Mean (SD) –0.4 (0.65) –0.3 (0.56)
LS mean (SE)* –0.4 (0.05) –0.4 (0.05) 0.0 (0.07)
95% CI† –0.5 to –0.3 –0.5 to –0.3 –0.2 to 0.1
P value* 0.5945
Change from
baseline to
Week 4
N 117 115
Mean (SD) –0.4 (0.62) –0.5 (0.64)
LS mean (SE) –0.4 (0.05) –0.5 (0.05) 0.1 (0.07)
95% CI –0.5 to –0.3 –0.6 to –0.4 –0.1 to 0.2
P value – – 0.3427
Change from
baseline to
Week 6
N 117 115
Mean (SD) –0.5 (0.68) –0.5 (0.70)
LS mean (SE) –0.5 (0.06) –0.5 (0.06) 0.0 (0.08)
95% CI –0.6 to –0.4 –0.6 to –0.4 –0.1 to 0.2
P value – – 0.6522
LS ¼ least squares; SR ¼ sustained release.
n Estimated from analysis of covariance model with treatment and center as
factors and baseline as covariate.
† Noninferiority considered if the upper bound of the CI o10.
Table V
Analyses of Assessment in Ankylosing Spondylitis responders at Week 6 and Week
12 (extension phase).
C200 D75 C200/C400 D75/C400
Week 6
Total* 54 54 54 54
Responders† 22 (40.7) 23 (42.6) 12 (22.2) 16 (29.6)
Week 12
Total* 51 53 46 51
Responders† 25 (49.0) 25 (47.2) 15 (32.6) 19 (37.3)
C200 ¼ celecoxib 200 mg once daily during double-blind and extension phase;
D75 ¼ diclofenac sustained release 75 mg once daily during double-blind and
extension phase; C200/C400 ¼ celecoxib 200 mg once daily during double-blind
phase and celecoxib 400 mg once daily during extension phase; D75/C400 ¼
diclofenac sustained release 75 mg once daily during double-blind phase and
celecoxib 400 mg once daily during extension phase.
n Total number of patients with data at baseline and week.
† Those patients showing improvement of at least 20% from baseline and
absolute improvement of at least 10 mm on a 0 to 100 scale in at least 3 of the
following 4 domains: Patient’s Global Assessment of Disease Activity, Patient’s
Assessment of Global Pain Intensity, Functional impairment according to Bath
Ankylosing Spondylitis Functional Index, Inﬂammation (deﬁned as mean value for
Bath Ankylosing Spondylitis Disease Activity Index morning stiffness intensity and
morning stiffness duration). In any domain for which a patient did not demonstrate
improvement, the patient must not have shown deterioration, with deterioration
deﬁned as a reduction that was both Z20% and Z10 mm. Values are presented
as n (%).
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Week 6 in the C200/C400 group was noticeably smaller than in the
C200 group. At Week 12, the change in baseline in the C200/C400
group was maintained (–0.6 [1.6] at Week 6 vs –0.6 [1.9] at Week
12) and in the D75/C400 group (–1.3 [2.1] at Week 6 vs –1.4 [2.1] at
Week 12).ASAS-20 responders
The percentage of ASAS-20 responders at Week 6 was 30.2% in
the celecoxib group and 34.2% in the diclofenac SR group (Table V).
The 2-sided 95% CI for the treatment difference was (–16.5 to 7.9).
At the end of the extension phase (Week 12), the percentage of
ASAS-20 responders was 49.0% in the C200 group and 47.2% in the
D75 group.ESR and CRP
The LS mean (SE) change from baseline at Week 6 in ESR was
–2.5 (1.3) mm/h in the celecoxib group and –1.8 (1.3) mm/h in the
diclofenac SR group (treatment difference and 2-sided 95% CI; –0.7
mm/h [–4.3 to 2.9 mm/h]). At Week 12, the mean (SD) change
from baseline was –3.5 (14.0) mm/h in the C200 group and –1.3
(11.1) mm/h in the D75 group. In patients who changed treatment
during the extension period, the mean (SD) change from baseline
at Week 12 was –6.3 (13.5) mm/h in the C200/C400 group and
–0.7 (19.5) mm/h in the D75/C400 group. For CRP, the LS mean (SE)
change from baseline at Week 6 was –4.2 (1.6) mg/L in the
celecoxib group and –2.7 (1.6) mg/L in the diclofenac SR group
(treatment difference and 2-sided 95% CI; –1.4 mg/L [–5.8 to
2.9 mg/L]). At Week 12, the mean (SD) change from baseline was
–4.6 (9.7) mg/L in the C200 group and –3.0 (13.2) mg/L in the D75
group. In patients who changed treatment during the extensionperiod, the mean (SD) change from baseline at Week 12 was –4.8
(24.7) mg/L in the C200/C400 group and –2.1 (20.9) mg/L in the
D75/C400 group.
Nocturnal pain, ﬁngertips to ﬂoor distance, and chest expansion
The LS mean (SE) change from baseline at Week 6 in nocturnal
pain was –15.4 (2.0) and –19.4 (2.0) in the celecoxib and diclofenac
SR groups, respectively (treatment difference and 2-sided 95% CI;
4.0 [–1.4 to 9.5]). At Week 12, the mean change from baseline
was –19.4 (22.5) in the C200 group and –27.5 (25.6) in the
D75 group.
The LS mean (SE) change in ﬁngertips to ﬂoor distance from
baseline at Week 6 was –2.8 (0.7) and –3.1 (0.7) in the celecoxib
and diclofenac SR groups, respectively. At Week 12, the mean (SD)
change from baseline was –3.0 (9.4) cm in the C200 group and
–3.7 (6.8) cm in the D75 group. The mean (SD) change from
baseline at Week 12 was –2.2 (8.0) in the C400 group.
The LS mean (SE) change from baseline at Week 6 in chest
expansion was 0.7 (0.1) in the celecoxib group and 0.6 (0.1) in the
diclofenac SR group. At Week 12, the mean change from baseline
was 0.8 (1.3) cm in the C200 group and 0.8 (1.4) cm in the D75
group. The mean change from baseline at Week 12 was 0.8 (1.2)
cm in the C400 group.
Safety proﬁle
AEs occurring in both treatment phases by patient treatment
group are summarized in Table VI. All were mild to moderate in
intensity; no serious AEs or deaths were reported during our
study. There were no clinically signiﬁcant changes in vital signs
during the double-blind period and 6-week extension period in
any of the treatment groups. During the double-blind period,
rescue medication in the form of acetaminophen/paracetamol
was taken by 3 patients in the celecoxib 200 mg once daily group
and 0 patients in the diclofenac SR 75 mg once daily group.
Discussion
Effective treatment of AS should meet the following 3 goals:
relief of back pain and stiffness, reduction of the underlying
Table VI
The incidence of treatment-emergent adverse events (AEs) (all causality and treatment-related) during the double-blind and extension phase.*
All causality Treatment-related
Celecoxib 200 mg once
daily (n ¼ 120)
Diclofenac SR 75 mg once
daily (n ¼ 120)
Celecoxib 200 mg once
daily (n ¼ 120)
Diclofenac SR 75 mg once
daily (n ¼ 120)
Double-blind phase
Number of patients
With AEs 11 (9.2) 9 (7.5) 5 (4.2) 8 (6.7)
Discontinued due to AEs 2 (1.7) 4 (3.3) 2 (1.7) 3 (2.5)
Number of patients with AEs by system organ class
Blood and lymphatic system disorders 1 (0.8) 0 1 (0.8) 0
Cardiac disorders 0 1 (0.8) 0 1 (0.8)
Eye disorder 0 1 (0.8) 0 0
Gastrointestinal disorders 3 (2.5) 4 (3.3) 2 (1.7) 4 (3.3)
Hepatobiliary disorders 0 2 (1.7) 0 2 (1.7)
Infections and infestations 4 (3.3) 2 (1.7) 0 1 (0.8)
Musculoskeletal and connective tissue disorders 1 (0.8) 0 0 0
Nervous system disorders 1 (0.8) 0 1 (0.8) 0
Respiratory, thoracic and mediastinal disorders 1 (0.8) 0 0 0
Skin and subcutaneous tissue disorders 1 (0.8) 0 1 (0.8) 0
All causality Treatment-related
Extension phase C200
(n ¼ 54)
D75
(n ¼ 55)
C200/C400
(n ¼ 53)
D75/C400
(n ¼ 54)
C200
(n ¼ 54)
D75
(n ¼ 55)
C200/C400
(n ¼ 53)
D75/C400
(n ¼ 54)
Number of patients
With AEs 0 6 (10.9) 5 (9.4) 6 (11.1) 0 4 (7.3) 3 (5.7) 3 (5.6)
Discontinued due to AEs 0 0 0 0 0 0 0 0
Number of patients with AEs by system organ class
Blood and lymphatic system disorders 0 1 (1.8) 0 0 0 0 0 0
Gastrointestinal disorders 0 0 0 1 (1.9) 0 0 0 0
Hepatobiliary disorders 0 1 (1.8) 0 1 (1.9) 0 1 (1.8) 0 1 (1.9)
Infections and infestations 0 0 1 (1.9) 2 (3.7) 0 0 0 0
Laboratory investigations† 0 4 (7.3) 4 (7.5) 2 (3.7) 0 3 (5.5) 3 (5.7) 2 (3.7)
C200 ¼ celecoxib 200 mg once daily during double-blind and extension phase; C200/C400 ¼ celecoxib 200 mg once daily during double-blind phase and celecoxib 400 mg
once daily during extension phase; D75 ¼ diclofenac sustained release 75 mg once daily during double-blind and extension phase; D75/C400 ¼ diclofenac sustained release
75 mg once daily during double-blind phase and celecoxib 400 mg once daily during extension phase.
n Patients were only counted once per treatment row; AEs occurring during the double-blind phase and up to 30 days after last dose (in double-blind phase) included.
Values are presented as n (%).
† Laboratory investigations include alanine aminotransferase increased, aspartate aminotransferase increased, red blood cells urine positive, transaminases increased,
weight decreased, and white blood cell count decreased.
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NSAIDs are widely used in the treatment of AS, a number of safety
and tolerability concerns surrounding their use (particularly over
the longer term) still exist. Meanwhile, data supporting the use of
alternative therapeutic options, such as COX-2 selective NSAIDs,
are lacking. In the absence of direct head-to-head comparisons
between COX-2 selective and nonselective NSAIDs in China, the
present study was conducted. Diclofenac SR was selected as the
active control because it is widely used by patients who have AS.26
The double-blind treatment duration of 6 weeks was chosen
because celecoxib has been shown to be statistically superior to
placebo in placebo-controlled clinical studies of 6 to 12 weeks’
duration in patients with AS.24,25 Using the ASAS-20 response
criteria, no changes in the response rates at Week 12 compared
with Week 6 were demonstrated. A 6-week extension was also
conducted to observe the safety proﬁle and to collect efﬁcacy data
for celecoxib 400 mg in Chinese patients.
Our study demonstrated that celecoxib 200 mg once daily was
noninferior to diclofenac SR 75 mg once daily in the treatment of
Chinese patients with AS. In addition, patients in the celecoxib 200
mg once daily group experienced similar improvements in pain
relief, disease activity, and physical function compared with
patients receiving diclofenac SR 75 mg once daily. This ﬁnding is
consistent with those of similarly designed studies in AS using the
same comparator treatment.24,25
According to previous reports,24,25 celecoxib 400 mg once daily
reduces some parameters of inﬂammation more effectively than
celecoxib 200 mg once daily, suggesting a possible dose-dependent effect and potentially better treatment outcomes with
the higher dose. The results of our analysis support this. At the end
of the extension period (Week 12), celecoxib 400 mg once daily
noticeably advanced the extent of improvements in patients who
did not achieve satisfactory improvement in signs and symptoms
after 6 weeks of treatment with celecoxib 200 mg once daily.
GI disorders are a well-known side effect of NSAID use;29,30
however, celecoxib, a selective inhibitor of the inducible form of
the COX enzyme (ie, COX-2), is thought to be better tolerated and
associated with fewer AEs than the more traditional nsNSAIDs that
act via nonselective inhibition of both COX-1 and COX-2.31–35 Notably,
in the Celecoxib versus Omeprazole and Diclofenac for at-Risk
Osteoarthritis and Rheumatoid Arthritis Patients trial, the rate of
predeﬁned and adjudicated clinically signiﬁcant upper and lower GI
events (the primary end point) was 4 times higher in patients with
arthritis at increased GI risk who were receiving diclofenac SR 75 mg
twice daily plus omeprazole 20 mg once daily than in those receiving
celecoxib 200 mg twice daily during 6 months of treatment.36
In our study, although GI disorders were the most frequently
reported treatment-related AEs in both treatment groups during
the double-blind phase, a similar number of GI AEs and discontin-
uations due to GI AEs were reported in patients receiving celecoxib
200 mg once daily compared with diclofenac SR 75 mg once daily.
Furthermore, patients receiving the higher celecoxib 400 mg once
daily dose throughout the 6-week extension phase also reported a
similar number of GI AEs and discontinuations compared with
patients receiving diclofenac SR 75 mg once daily. Our results,
which suggest that treatment with celecoxib is not only well
F. Huang et al. / Current Therapeutic Research 76 (2014) 126–133 133tolerated but associated with a low frequency of GI AEs are also
consistent with those of previous study outcomes in patients with
AS24,25 and arthritis.29,30,36Conclusions
Consistent with previous ﬁndings in AS, our results suggest that
the efﬁcacy of celecoxib 200 mg once daily is noninferior to
diclofenac SR 75 mg once daily over 6 weeks of treatment in
Chinese patients with AS. Furthermore, the use of celecoxib 400
mg once daily was not associated with any additional AEs or
tolerability issues compared with diclofenac SR 75 mg once daily
over a 6-week treatment extension.Acknowledgments
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